Conference abstractPublished 2018
A new drug delivery system for targeted therapy of ovarian cancermicroscopy
University of Sydney, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ovarian cancer is the seventh most common cancer in women worldwide. It often has no symptoms at the early stages, so the disease is generally advanced when it is diagnosed. Primary and larger tumor nodules may be removed surgically. However, micronodular and floating tumor colonies, which are spread within the peritoneal cavity, cannot be adequately treated by surgery and require extensive chemotherapy. Targeted drug therapy has numerous benefits including the maintenance of low blood-to-cell drug concentration ratio, which helps to reduce therapy-limiting side effects and increase anticancer effectiveness. We have developed a new drug delivery system, which targets antineoplastic agents to the ovarian cancer cells through a ligand of luteinizing hormone-releasing hormone (LHRH) receptors. LHRH receptors are overexpressed in in ovarian and some other cancer cells and are not expressed in the most part of healthy human organs. We have taken advantage of this differential receptor expression by attaching a new derivative of the LHRH peptide to the outer surface of novel polymer nanoparticles. These nanoparticles are loaded with curcumina as the model drug, a non-toxic plant extract that has recently attracted much attention in medicine due to its remarkable therapeutical actions. It is called the “next generation multipurpose drug” and is the active constituent of the Indian spice turmeric. However, it suffers from a very poor metabolic stability and bioavailability due to low water solubility. In this study we have demonstrated that our advanced formulation strategy has overcome many of the hurdles associated with poorly soluble drug molecules like curcumin. This drug delivery system has shown promising potentials to be effectively used as a medication and also target anticancer agents specifically to the ovarian cancer.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAndrology & Gynecology: Current Research
- SubjectNephrology & Urology
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Pegah Varamini”
